Using proprietary microfluidic technology, ScreenIn3D provides next-generation, high quality screening services that help drug developers to validate the effectives of their compounds and treatment on physiologically relevant, preclinical in vitro models of disease. Our unique ex vivo microfluidic platform offers advanced and customisable drug screening assays using primary cells and human tissue in a 3D environment for preclinical and combination studies.
